Skip to content

​INBRAIN’s “rice‑sized” graphene BCI chip marks new phase in Merck collaboration 

​INBRAIN’s “rice‑sized” graphene BCI chip marks new phase in Merck collaboration 

INBRAIN Neuroelectronics has announced a step forward in its long‑running collaboration with Merck, highlighting a new bidirectional, “rice‑sized” graphene BCI chip and a fresh push toward commercialization, including a speech‑decoding clinical trial.

The collaboration between INBRAIN and Merck was first established in 2021, with the goal of developing graphene‑based bioelectronic therapies for serious chronic diseases. This framework is now shifting from high‑level R&D into product‑oriented development, with Merck signaling commercialization intent around INBRAIN’s BCI‑Tx platform and its latest device iteration.

 ​

INBRAIN Neuroelectronics has announced a step forward in its long‑running collaboration with Merck, highlighting a new bidirectional, “rice‑sized” graphene BCI chip and a fresh push toward commercialization, including a speech‑decoding clinical trial.The collaboration between INBRAIN and Merck was first established in 2021, with the goal of developing graphene‑based bioelectronic therapies for serious chronic diseases. This framework is now shifting from high‑level R&D into product‑oriented development, with Merck signaling commercialization intent around INBRAIN’s BCI‑Tx platform and its latest device iteration. 

Read More Graphene-Info – Graphene industry portal